Which has stronger earnings & valuation, SEPN or KMDA?

Kamada has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Septerna $45.95M 38.42 -$48.88M -$0.81 N/A Kamada $181.68M 2.25 $20.20M $0.35 20.34

Is SEPN or KMDA more profitable?

Kamada has a net margin of 11.21% compared to Septerna's net margin of -49.88%. Kamada's return on equity of 7.73% beat Septerna's return on equity. Company Net Margins Return on Equity Return on Assets Septerna -49.88% -12.72% -8.87% Kamada 11.21% 7.73% 5.41%

Does the media favor SEPN or KMDA?

In the previous week, Septerna had 3 more articles in the media than Kamada. MarketBeat recorded 7 mentions for Septerna and 4 mentions for Kamada. Septerna's average media sentiment score of 0.53 beat Kamada's score of 0.21 indicating that Septerna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Septerna 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kamada 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, ZYME or KMDA?

Kamada has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zymeworks $105.96M 16.12 -$81.13M -$2.02 N/A Kamada $181.68M 2.25 $20.20M $0.35 20.34

Is ZYME or KMDA more profitable?

Kamada has a net margin of 11.21% compared to Zymeworks' net margin of -405.31%. Kamada's return on equity of 7.73% beat Zymeworks' return on equity. Company Net Margins Return on Equity Return on Assets Zymeworks -405.31% -72.30% -37.18% Kamada 11.21% 7.73% 5.41%

Does the media favor ZYME or KMDA?

In the previous week, Zymeworks had 12 more articles in the media than Kamada. MarketBeat recorded 16 mentions for Zymeworks and 4 mentions for Kamada. Kamada's average media sentiment score of 0.21 beat Zymeworks' score of -0.01 indicating that Kamada is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Kamada 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, KMDA or ANAB?

Kamada has higher earnings, but lower revenue than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kamada $181.68M 2.25 $20.20M $0.35 20.34 AnaptysBio $234.60M 7.17 -$13.23M -$1.08 N/A

Is KMDA or ANAB more profitable?

Kamada has a net margin of 11.21% compared to AnaptysBio's net margin of -11.53%. Kamada's return on equity of 7.73% beat AnaptysBio's return on equity. Company Net Margins Return on Equity Return on Assets Kamada 11.21% 7.73% 5.41% AnaptysBio -11.53% N/A -7.75%

Does the media refer more to KMDA or ANAB?

In the previous week, Kamada had 1 more articles in the media than AnaptysBio. MarketBeat recorded 4 mentions for Kamada and 3 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 0.45 beat Kamada's score of 0.21 indicating that AnaptysBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AnaptysBio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, KMDA or AAPG?

Kamada has higher revenue and earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kamada $181.68M 2.25 $20.20M $0.35 20.34 Ascentage Pharma Group International $82.10M 21.26 -$177.71M N/A N/A

Which has better earnings and valuation, KMDA or VIR?

Kamada has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kamada $181.68M 2.25 $20.20M $0.35 20.34 Vir Biotechnology $68.56M 22.21 -$437.99M -$1.86 N/A

Does the media refer more to KMDA or VIR?

In the previous week, Vir Biotechnology had 9 more articles in the media than Kamada. MarketBeat recorded 13 mentions for Vir Biotechnology and 4 mentions for Kamada. Vir Biotechnology's average media sentiment score of 0.33 beat Kamada's score of 0.21 indicating that Vir Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vir Biotechnology 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Kamada (KMDA) Competitors

$7.12 -0.15 (-1.99%)

As of 12:32 PM Eastern

Compare

KMDA vs. SEPN, ZYME, ANAB, AAPG, and VIR

Should you buy Kamada stock or one of its competitors? MarketBeat compares Kamada with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kamada include Septerna (SEPN), Zymeworks (ZYME), AnaptysBio (ANAB), Ascentage Pharma Group International (AAPG), and Vir Biotechnology (VIR). These companies are all part of the "biotechnology" industry.

How does Kamada compare to Septerna?

Septerna (NASDAQ:SEPN) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Kamada has a net margin of 11.21% compared to Septerna's net margin of -49.88%. Kamada's return on equity of 7.73% beat Septerna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Kamada	11.21%	7.73%	5.41%

Septerna currently has a consensus price target of $45.89, indicating a potential upside of 17.18%. Kamada has a consensus price target of $13.00, indicating a potential upside of 82.58%. Given Kamada's stronger consensus rating and higher possible upside, analysts clearly believe Kamada is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Septerna had 3 more articles in the media than Kamada. MarketBeat recorded 7 mentions for Septerna and 4 mentions for Kamada. Septerna's average media sentiment score of 0.53 beat Kamada's score of 0.21 indicating that Septerna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kamada	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

20.4% of Kamada shares are held by institutional investors. 5.8% of Septerna shares are held by insiders. Comparatively, 36.1% of Kamada shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Kamada has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	38.42	-$48.88M	-$0.81	N/A
Kamada	$181.68M	2.25	$20.20M	$0.35	20.34

Septerna has a beta of 2.29, indicating that its stock price is 129% more volatile than the broader market. Comparatively, Kamada has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

Summary

Kamada beats Septerna on 11 of the 17 factors compared between the two stocks.

How does Kamada compare to Zymeworks?

Zymeworks (NASDAQ:ZYME) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

Zymeworks has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Kamada has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

Kamada has a net margin of 11.21% compared to Zymeworks' net margin of -405.31%. Kamada's return on equity of 7.73% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-405.31%	-72.30%	-37.18%
Kamada	11.21%	7.73%	5.41%

In the previous week, Zymeworks had 12 more articles in the media than Kamada. MarketBeat recorded 16 mentions for Zymeworks and 4 mentions for Kamada. Kamada's average media sentiment score of 0.21 beat Zymeworks' score of -0.01 indicating that Kamada is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Kamada	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kamada has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	16.12	-$81.13M	-$2.02	N/A
Kamada	$181.68M	2.25	$20.20M	$0.35	20.34

92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 20.4% of Kamada shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by insiders. Comparatively, 36.1% of Kamada shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Zymeworks presently has a consensus target price of $38.22, indicating a potential upside of 58.80%. Kamada has a consensus target price of $13.00, indicating a potential upside of 82.58%. Given Kamada's stronger consensus rating and higher probable upside, analysts plainly believe Kamada is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Kamada beats Zymeworks on 11 of the 17 factors compared between the two stocks.

How does Kamada compare to AnaptysBio?

Kamada (NASDAQ:KMDA) and AnaptysBio (NASDAQ:ANAB) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Kamada has higher earnings, but lower revenue than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$181.68M	2.25	$20.20M	$0.35	20.34
AnaptysBio	$234.60M	7.17	-$13.23M	-$1.08	N/A

Kamada currently has a consensus target price of $13.00, indicating a potential upside of 82.58%. AnaptysBio has a consensus target price of $82.00, indicating a potential upside of 44.26%. Given Kamada's stronger consensus rating and higher possible upside, equities analysts plainly believe Kamada is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
AnaptysBio	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

20.4% of Kamada shares are held by institutional investors. 36.1% of Kamada shares are held by insiders. Comparatively, 31.5% of AnaptysBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Kamada has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

Kamada has a net margin of 11.21% compared to AnaptysBio's net margin of -11.53%. Kamada's return on equity of 7.73% beat AnaptysBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.21%	7.73%	5.41%
AnaptysBio	-11.53%	N/A	-7.75%

In the previous week, Kamada had 1 more articles in the media than AnaptysBio. MarketBeat recorded 4 mentions for Kamada and 3 mentions for AnaptysBio. AnaptysBio's average media sentiment score of 0.45 beat Kamada's score of 0.21 indicating that AnaptysBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AnaptysBio	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kamada beats AnaptysBio on 12 of the 16 factors compared between the two stocks.

How does Kamada compare to Ascentage Pharma Group International?

Kamada (NASDAQ:KMDA) and Ascentage Pharma Group International (NASDAQ:AAPG) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

Kamada currently has a consensus price target of $13.00, indicating a potential upside of 82.58%. Ascentage Pharma Group International has a consensus price target of $46.43, indicating a potential upside of 148.41%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, analysts plainly believe Ascentage Pharma Group International is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20

Kamada has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market.

Kamada has higher revenue and earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$181.68M	2.25	$20.20M	$0.35	20.34
Ascentage Pharma Group International	$82.10M	21.26	-$177.71M	N/A	N/A

Kamada has a net margin of 11.21% compared to Ascentage Pharma Group International's net margin of 0.00%. Kamada's return on equity of 7.73% beat Ascentage Pharma Group International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.21%	7.73%	5.41%
Ascentage Pharma Group International	N/A	N/A	N/A

20.4% of Kamada shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Ascentage Pharma Group International had 1 more articles in the media than Kamada. MarketBeat recorded 5 mentions for Ascentage Pharma Group International and 4 mentions for Kamada. Ascentage Pharma Group International's average media sentiment score of 0.23 beat Kamada's score of 0.21 indicating that Ascentage Pharma Group International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascentage Pharma Group International	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kamada beats Ascentage Pharma Group International on 8 of the 15 factors compared between the two stocks.

How does Kamada compare to Vir Biotechnology?

Kamada (NASDAQ:KMDA) and Vir Biotechnology (NASDAQ:VIR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Kamada has a net margin of 11.21% compared to Vir Biotechnology's net margin of -638.88%. Kamada's return on equity of 7.73% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.21%	7.73%	5.41%
Vir Biotechnology	-638.88%	-29.99%	-23.62%

In the previous week, Vir Biotechnology had 9 more articles in the media than Kamada. MarketBeat recorded 13 mentions for Vir Biotechnology and 4 mentions for Kamada. Vir Biotechnology's average media sentiment score of 0.33 beat Kamada's score of 0.21 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vir Biotechnology	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

20.4% of Kamada shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 36.1% of Kamada shares are held by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Kamada has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market.

Kamada presently has a consensus price target of $13.00, indicating a potential upside of 82.58%. Vir Biotechnology has a consensus price target of $20.63, indicating a potential upside of 129.19%. Given Vir Biotechnology's higher possible upside, analysts plainly believe Vir Biotechnology is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Kamada has higher revenue and earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$181.68M	2.25	$20.20M	$0.35	20.34
Vir Biotechnology	$68.56M	22.21	-$437.99M	-$1.86	N/A

Summary

Kamada beats Vir Biotechnology on 9 of the 17 factors compared between the two stocks.

Get Kamada News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KMDA vs. The Competition

Export

Metric	Kamada	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$410.59M	$3.71B	$7.03B	$12.96B
Dividend Yield	2.63%	3.76%	2.58%	10.20%
P/E Ratio	20.40	9.06	269.91	24.87
Price / Sales	2.25	1,278.42	654.69	108.21
Price / Cash	11.90	44.95	28.89	37.44
Price / Book	1.52	17.97	11.40	6.45
Net Income	$20.20M	-$13.25M	$3.45B	$347.50M
7 Day Performance	-1.52%	5.58%	3.66%	3.77%
1 Month Performance	N/A	-1.60%	-0.49%	-0.40%
1 Year Performance	N/A	61.32%	77.51%	23.55%

Kamada Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KMDA Kamada	4.9629 of 5 stars	$7.13 -2.0%	$13.00 +82.5%	+2.1%	$410.30M	$181.68M	20.39	360	Upcoming Earnings Gap Down
SEPN Septerna	2.0357 of 5 stars	$36.88 +5.4%	$45.89 +24.4%	+232.2%	$1.66B	$45.95M	N/A	N/A	News Coverage
ZYME Zymeworks	2.862 of 5 stars	$22.62 +3.7%	$37.33 +65.0%	+95.8%	$1.65B	$105.96M	N/A	460	Earnings Report Analyst Forecast Analyst Revision
ANAB AnaptysBio	3.129 of 5 stars	$53.93 +0.5%	$82.00 +52.0%	+169.2%	$1.60B	$234.60M	N/A	100
AAPG Ascentage Pharma Group International	4.0899 of 5 stars	$16.80 -0.1%	$46.43 +176.4%	-54.7%	$1.57B	$82.10M	N/A	600

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KMDA) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kamada (KMDA) Competitors